次要组织相容性抗原与异基因造血细胞移植后结局的关联
研究在2249对接受异基因造血细胞移植的急性髓系白血病和骨髓增生异常综合征供受者对中分析预测的次要组织相容性抗原与临床结局的关联。I类次要组织相容性抗原数量高于人群中位数的患者移植物抗宿主病死亡率风险增加(HR=1.39,95%CI=1.01,1.77,p=.046)。特定I类和II类次要组织相容性抗原分别与移植物抗宿主病死亡率、无白血病生存、疾病相关死亡和治疗相关死亡相关。
要点
- I类次要组织相容性抗原数量高于人群中位数的患者移植物抗宿主病死亡率风险增加(HR=1.39)。
- DLRCKYISL(GSTP)与移植物抗宿主病死亡率增加相关(HR=2.84)。
- WEHGPTSLL(CRISPLD2)和STSPTTNVL(SERPINF2)呈剂量反应关系加性增加死亡风险。
核心结论
- 预测的I类次要组织相容性抗原数量高于人群中位数与移植物抗宿主病死亡率风险增加相关(HR=1.39,95%CI=1.01,1.77,p=.046)。
- 特定I类和II类次要组织相容性抗原肽与移植物抗宿主病死亡率、无白血病生存、疾病相关死亡和治疗相关死亡存在关联。
研究设计与样本
- 研究纳入2249对接受异基因造血细胞移植治疗的急性髓系白血病和骨髓增生异常综合征供受者对。
- 采用改进的次要组织相容性抗原预测方法,在两个大型患者队列中分析预测的次要组织相容性抗原数量及单个次要组织相容性抗原与临床结局的关联。
主要发现
- I类次要组织相容性抗原数量高于人群中位数的患者移植物抗宿主病死亡率风险增加(HR=1.39,95%CI=1.01,1.77,p=.046)。
- DLRCKYISL(GSTP)与移植物抗宿主病死亡率增加相关(HR=2.84,95%CI=1.52,5.31,p=.01)。
- WEHGPTSLL(CRISPLD2)与无白血病生存降低相关(HR=1.94,95%CI=1.27,2.95,p=.044)。
- STSPTTNVL(SERPINF2)与疾病相关死亡增加相关(HR=2.32,95%CI=1.5,3.6,p=.008)。
- YQEIAAIPSAGRERQ(TACC2)与治疗相关死亡风险增加相关(HR=3.05,95%CI=1.75,5.31,p=.02)。
关键数值与推荐
- WEHGPTSLL和STSPTTNVL均存在于HLA单倍型B*40:01-C*03:04中,与全因死亡和疾病相关死亡增加及无白血病生存降低呈正剂量反应关系,表明这两个次要组织相容性抗原以加性方式贡献死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of minor histocompatibility antigens (mHAs) in mediating graft versus leukemia and graft versus host disease (GvHD) following allogeneic hematopoietic cell transplantation (alloHCT) is recognized but not well-characterized. By implementing improved methods for mHA prediction in two large patient cohorts, this study aimed to comprehensively explore the role of mHAs in alloHCT by analyzing whether (1) the number of predicted mHAs, or (2) individual mHAs are associated with clinical outcomes. The study population consisted of 2249 donor-recipient pairs treated for acute myeloid leukemia and myelodysplastic syndrome with alloHCT. A Cox proportional hazard model showed that patients with a class I mHA count greater than the population median had an increased hazard of GvHD mortality (hazard ratio [HR] = 1.39, 95% confidence interval [CI] = 1.01, 1.77, p = .046). Competing risk analyses identified the class I mHAs DLRCKYISL (GSTP), WEHGPTSLL (CRISPLD2), and STSPTTNVL (SERPINF2) were associated with increased GVHD mortality (HR = 2.84, 95% CI = 1.52, 5.31, p = .01), decreased leukemia-free survival (LFS) (HR = 1.94, 95% CI = 1.27, 2.95, p = .044), and increased disease-related mortality (DRM) (HR = 2.32, 95% CI = 1.5, 3.6, p = .008), respectively. One class II mHA YQEIAAIPSAGRERQ (TACC2) was associated with increased risk of treatment-related mortality (TRM) (HR = 3.05, 95% CI = 1.75, 5.31, p = .02). WEHGPTSLL and STSPTTNVL were both present within HLA haplotype B*40:01-C*03:04 and showed a positive dose-response relationship with increased all-cause mortality and DRM and decreased LFS, indicating these two mHAs contribute to the risk of mortality in an additive manner. Our study reports the first large-scale investigation of the associations of predicted mHA peptides with clinical outcomes following alloHCT.
引用
- Jadi O, Tang H, Olsen K, et al. Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation. Am J Hematol. 2023. PMID: 37052167. doi:10.1002/ajh.26925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。